ArticleJournal of Crohn's & colitis2022
Faecal Myeloperoxidase as a Biomarker of Endoscopic Activity in Inflammatory Bowel Disease.
Article in Journal of Crohn's & colitis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 57 citations in OpenAlex.
- Analysis of multiplexed SERS-based lateral flow assays: turning qualitative into quantitative for inflammatory bowel disease monitoring.The Analyst · 2026Article
- The Utility of Faecal Biomarkers in the Discrimination Between Acute Gastroenteritis and Inflammatory Bowel Disease.Biomedicines · 2026Article
- Persistent Gene Activation as a Molecular Signature of Ulcerative Colitis Progression to Colorectal Cancer.Digestive diseases and sciences · 2026Article
- HOCl-Mediated Bromothymol Blue Bleaching and Carbon Dot Fluorescence Recovery for Fecal Myeloperoxidase Quantification in Ulcerative Colitis.Journal of fluorescence · 2026Review
- Factors Associated With Loss of Fecal Biomarker Accuracy During Routine Assessment of Inflammatory Bowel Disease.JGH open : an open access journal of gastroenterology and hepatology · 2026Article
- Dietary tryptophan ameliorates metalaxyl-induced colitis by restoring microbial tryptophan metabolism and aryl hydrocarbon receptor activation.Frontiers in nutrition · 2026Article
- The Roles of Four Neutrophil-Derived Proteins as Non-Invasive Biomarkers in the Assessment of Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- Myeloperoxidase Luminol Reaction - A Novel Faecal Assay for Predicting Colonoscopy Findings in Patients with Ulcerative Colitis: A Pilot Cross-Sectional Clinical Study.Advanced healthcare materials · 2026Article
- Fecal intestinal inflammatory biomarkers in piglets: analytical validation, homogeneity and stability studies.Veterinary and animal science · 2025Article
- Plasma Calprotectin and Myeloperoxidase as Biomarkers in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- From Cytokines to Biomarkers: Mapping the Immunopathology of Inflammatory Bowel Disease.Cells · 2025Review
- Myeloperoxidase Enzyme Activity in Feces Reflects Endoscopic Severity in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Neutrophils and NETs in Pathophysiology and Treatment of Inflammatory Bowel Disease.International journal of molecular sciences · 2025Review
- Repurposing Atorvastatin, HMGCO-A Reductase Inhibitor, in Patients with Ulcerative Colitis: A Randomized Controlled Study.Journal of clinical medicine · 2025Article
- Assessing endoscopic remission in small bowel Crohn's disease: Are markers enough?World journal of gastrointestinal endoscopy · 2025Article
- Fecal Myeloperoxidase Levels Reflect Disease Activity in Children With Crohn's Disease.Inflammatory bowel diseases · 2025Observational
- ModifiedWorld journal of gastroenterology · 2025Article
- Comparison of Fecal Calprotectin and Myeloperoxidase in Predicting Outcomes in Inflammatory Bowel Disease.Inflammatory bowel diseases · 2025Article
- Ulcerative Colitis: Advances in Pathogenesis, Biomarkers, and Therapeutic Strategies.Pharmacogenomics and personalized medicine · 2025Review
- Neutrophil diversity and function in health and disease.Signal transduction and targeted therapy · 2024Review
Corrections and comments
- Commented on by
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsInflammatory bowel disease [IBD], consisting of Crohn's disease [CD] and ulcerative colitis [UC], is a relapsing-remitting illness. Treat-to-target IBD management strategies require monitoring of gastrointestinal inflammation. This study aimed to investigate faecal myeloperoxidase [fMPO], a neutrophil granule enzyme, as a biomarker of IBD activity.
methodsProspectively recruited participants with IBD, undergoing ileocolonoscopy for disease assessment, provided biological samples and completed symptom questionnaires prior to endoscopy. fMPO, C-reactive protein [CRP], and faecal calprotectin [fCal] were compared with validated endoscopic indices [simple endoscopic score for CD and UC endoscopic index of severity]. Receiver operating characteristic [ROC] curves assessed the performance of fMPO, CRP, and fCal in predicting endoscopic disease activity. Baseline biomarkers were used to predict a composite endpoint of complicated disease at 12 months [need for escalation of biologic/immunomodulator due to relapse, steroid use, IBD-related hospitalisation, and surgery].
resultsA total of 172 participants were recruited [91 female, 100 with CD]. fMPO was significantly correlated with endoscopic activity in both CD [r = 0.53, p < 0.01] and UC [r = 0.63, p < 0.01], and with fCal in all patients with IBD [r = 0.82, p < 0.01]. fMPO was effective in predicting moderate-to-severely active CD [AUROC 0.86, p < 0.01] and UC [AUROC 0.92, p < 0.01]. Individuals with a baseline fMPO > 26 µg/g were significantly more likely to reach the composite outcome at 12 months (hazard ratio [HR] 3.71, 95% confidence interval [CI] 2.07-6.64, p < 0.01).
conclusionsFaecal myeloperoxidase is an accurate biomarker of endoscopic activity in IBD and predicted a more complicated IBD course during follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.